Tzield (teplizumab-mzwv) one-time 14-day course to delay Stage 3 type 1 diabetes
Defines UnitedHealthcare medical benefit drug coverage criteria for Tzield (teplizumab-mzwv) to delay onset of Stage 3 type 1 diabetes in pediatric and adult patients, including eligibility, prescribing/diagnostic requirements, dosing conformity to FDA labeling, lifetime limit, and related billing/applicability notes.
Updated Clinical Evidence and References sections to reflect the most current information.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.